Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
12.74
-0.34 (-2.60%)
At close: Mar 20, 2026, 4:00 PM EDT
12.46
-0.28 (-2.20%)
Pre-market: Mar 23, 2026, 5:12 AM EDT
Cullinan Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts that cover Cullinan Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $30.11, which forecasts a 136.34% increase in the stock price over the next year. The lowest target is $22 and the highest is $38.
Price Target: $30.11 (+136.34%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cullinan Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 8 | 7 |
| Buy | 2 | 1 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 8 | 8 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $34 → $36 | Buy | Maintains | $34 → $36 | +182.57% | Mar 11, 2026 |
| Citigroup | Citigroup | Strong Buy Initiates $33 | Strong Buy | Initiates | $33 | +159.03% | Feb 17, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +135.48% | Feb 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $26 → $27 | Strong Buy | Maintains | $26 → $27 | +111.93% | Jan 8, 2026 |
| Wedbush | Wedbush | Buy Maintains $25 → $34 | Buy | Maintains | $25 → $34 | +166.88% | Dec 9, 2025 |
Financial Forecast
Revenue This Year
16.67M
Revenue Next Year
29.99M
from 16.67M
Increased by 79.85%
EPS This Year
-3.12
from -3.72
EPS Next Year
-3.00
from -3.12
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 49.6M | 105.0M | |||
| Avg | 16.7M | 30.0M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 529.8% | |||
| Avg | - | 79.9% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.25 | -0.85 | |||
| Avg | -3.12 | -3.00 | |||
| Low | -3.89 | -4.36 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.